Table 2 The final height of the included participants.

Variables	Combination therapy (n = 54)	Monotherapy (n = 80)	No treatment (n = 48)	F	P	P₁	P₂	P₃
Before adjustment
FAH	160.31 (5.11)	160.61 (5.03)	160.35 (5.06)	0.068	0.935	0.739	0.964	0.785
FAH-PAH₀	4.08 (4.22)	1.83 (3.61)	− 0.51 (3.81)	17.997	< 0.001	0.001	< 0.001	0.001
FAH-TH	5.27 (4.51)	3.88 (4.37)	2.97 (4.98)	3.308	0.039	0.086	0.012	0.278
FAHSDS	0.24 (0.87)	0.31 (0.93)	0.24 (0.92)	0.153	0.858	0.636	0.994	0.655
FAHSDS-H₀SDS	0.21 (0.72)	− 0.14 (0.62)	− 0.54 (0.78)	15.051	< 0.001	0.004	< 0.001	0.002
After adjustment
FAH	162.58 (0.46)	160.25 (0.35)	158.39 (0.47)	17.682	< 0.001	< 0.001	< 0.001	< 0.001
FH-PAH₀	4.00 (0.46)	1.68 (0.36)	− 0.18 (0.47)	17.682	< 0.001	< 0.001	< 0.001	< 0.001
FH-TH	6.18 (0.46)	3.85 (0.35)	1.99 (0.47)	17.682	< 0.001	< 0.001	< 0.001	< 0.001
FHSDS	0.66 (0.08)	0.24 (0.06)	− 0.13 (0.08)	21.250	< 0.001	< 0.001	< 0.001	< 0.001
FHSDS-H₀SDS	0.26 (0.08)	− 0.17 (0.06)	− 0.54 (0.08)	21.303	< 0.001	< 0.001	< 0.001	< 0.001

P₁: combination therapy VS monotherapy; P₂ combination therapy VS no treatment; P₃: monotherapy VS no treatment; FAH: final adult height; FAH-PAH₀: height gain, refers to the difference between final adult height and predicted adult height before treatment; FAH-TH: genetic height gain, refers to the difference between final adult height and target height; FAHSDS: the standard deviation score of final adult height; FAHSDS- H₀SDS: HSDS gain, refers to the difference between the standard deviation score of final adult height and that of height before treatment.
*The age of puberty onset, age of treatment initiation, the standard deviation score of height before treatment, target height, bone age before treatment, and predicted final height before treatment were included as covariates in the general linear model to adjust for the impacts of confounding factors.
Significant values are in [bold].

Search